MorphoSys AG announced yesterday that it has received a milestone payment from Novartis in connection with the clinical trial application (CTA) and projected initiation of a phase 1 clinical trial of a HuCAL-derived, fully human antibody in the therapeutic area of inflammatory diseases.
"Our fifth clinical program within the Novartis alliance clearly underpins the success of this collaboration," commented Dr Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "This program is one of seven that have moved into the clinic in 2010, which was an outstanding year in this regard."
MorphoSys's clinical pipeline now comprises nine partnered programs in Phase 1 and five in Phase 2 development as well as the Company's proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.
MorphoSys
